布洛芬注射液治疗急性发热患者的经济学评价

Economic Evaluation of Ibuprofen Injection in the Treatment of Acute Fever

目的对布洛芬注射液治疗急性发热患者进行经济学评价,为临床实践和政府决策提供科学证据。方法从健康保健体系角度出发,基于布洛芬注射液的国内Ⅲ期临床研究,构建短期决策树分析模型,分别计算治疗所需的成本和健康产出。使用3倍人均国内生产总值(GDP)作为支付意愿阈值,比较布洛芬注射液和安慰剂组的成本-效用,并进行单因素敏感性分析和概率敏感性分析。结果基线研究结果显示,布洛芬注射液和安慰剂组的人均治疗成本分别为201.14元和187.08元,产出分别为0.86质量调整生命日(QALD)和0.75 QALD,增量成本-效用比(ICUR)为127.49元/QALD,小于支付意愿阈值。敏感性分析支持结果的稳健性。结论从健康保健体系角度出发,基于短期的成本-效用分析,布洛芬注射液具有良好的经济学优势。

Objective To evaluate the economy of ibuprofen injection in the treatment of acute fever, and to provide scientific evidence for clinical practice and government decision-making. Method From the perspective of health security system, based on the domestic phase Ⅲ clinical study of ibuprofen injection, a short-term decision tree analysis model was constructed to calculate the cost and health outcomes required for treatment. The study compared the cost-utility ratio of ibuprofen injection and placebo group, uses the 3 times GDP per capita as the payment threshold, and conducted single factor sensitivity analysis and probability sensitivity analysis. Results The baseline study showed that the per capita treatment costs for the ibuprofen and placebo groups were 201.14 and 187.08,and the yields were 0.86 quality adjusted life day(QALD) and 0.75 QALD, respectively. The ICUR was 127.49 yuan/QALD, which was less than the payment threshold. Sensitivity analysis supported the robustness of the results. Conclusion From the perspective of the health care system, Ibuprofen injection has good economic advantages based on short-term cost-utility analysis.